Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 4/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.47 |
| ▸ | CCKBR | P32239 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22984879 | 0.95 | DPP3 (0.46) | DPP3CXCR4CCKBRCASP1CASP3 | |
| SCHEMBL23008651 | 0.91 | CCKBR (0.46) | DPP3CXCR4CCKBRCASP1CASP3 | |
| SCHEMBL23008652 | 0.90 | DPP3 (0.47) | DPP3CXCR4CCKBRCASP1CASP3 | |
| SCHEMBL21955932 | 0.88 | ERBB2 (0.52) | CXCR4CCKBR | |
| SCHEMBL20614596 | 0.85 | DPP3 (0.46) | DPP3CXCR4CCKBRCASP1CASP3 | |
| SCHEMBL21955853 | 0.84 | ERBB2 (0.52) | CCKBR | |
| SCHEMBL24245857 | 0.83 | DPP3 (0.54) | DPP3 | |
| SCHEMBL22984866 | 0.83 | CCKBR (0.49) | DPP3CCKBR | |
| SCHEMBL21956028 | 0.82 | IL23R (0.58) | CXCR4CCKBR | |
| SCHEMBL22753495 | 0.80 | CASP1 (0.57) | CCKBRCASP1CASP3CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11241473-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2022-02-08 | — | — | US | disclosed |
| US-20210147484-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| US-20210046145-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| US-10857196-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10857196-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | DPP3 83/4885CXCR4 55/4885CCKBR 17/4885 |
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | DPP3 83/4885CXCR4 55/4885CCKBR 17/4885 |
| US-20210046145-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | DPP3 83/4885CXCR4 55/4885CCKBR 17/4885 |
| US-20210147484-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | DPP3 83/4885CXCR4 55/4885CCKBR 17/4885 |
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | DPP3 83/4885CXCR4 55/4885CCKBR 17/4885 |
| US-11241473-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | DPP3 83/4885CXCR4 55/4885CCKBR 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.